Xianglin Du


Affiliation: Texas Medical Center
Country: USA


  1. Fu S, Wang M, Li R, Lairson D, Zhao B, Du X. Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas. Cancer Epidemiol. 2018;58:89-97 pubmed publisher
    ..002) datasets. Survival outcome for MCL patients improved from 1995 to 2013, especially for patients with advanced-stage tumors, potentially reflecting the impact of the introduction of novel agents and new therapeutic regimens. ..
  2. Nguyen C, Lairson D, Swartz M, Du X. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer. J Racial Ethn Health Disparities. 2018;: pubmed publisher
    ..White, Hispanic men and men living in the South initiate ADT earlier. Significant racial disparities exist in the receipt and use of this highly beneficial therapy, and there are geographic variations in the utilization of this therapy. ..
  3. request reprint
    Du X, Sun C, Milam M, Bodurka D, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:660-9 pubmed
    ..Although adjuvant chemotherapy was effective in prolonging survival, substantial numbers of women with ovarian cancer still did not receive chemotherapy. ..
  4. Du X, Xia R, Burau K, Liu C. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol. 2011;28 Suppl 1:S80-90 pubmed publisher
    ..Carefully monitoring cardiac functions in patients receiving anthracycline and trastuzumab is warranted. ..
  5. Du X, Lin C, Johnson N, Altekruse S. Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. Cancer. 2011;117:3242-51 pubmed publisher
    ..Favorable survival was associated with higher socioeconomic status. Racial disparities in survival persisted after adjusting for individual-level socioeconomic factors and treatment for patients with breast and prostate cancer. ..
  6. Du X, Zhang Y. Risks of Venous Thromboembolism, Stroke, Heart Disease, and Myelodysplastic Syndrome Associated With Hematopoietic Growth Factors in a Large Population-Based Cohort of Patients With Colorectal Cancer. Clin Colorectal Cancer. 2015;14:e21-31 pubmed publisher
    ..The use of CSFs and ESAs was also significantly associated with a moderately increased risk of VTE and a slightly elevated risk of heart disease. ..
  7. Du X, Xia R, Liu C, Cormier J, Xing Y, Hardy D, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009;115:5296-308 pubmed publisher
  8. Du X, Parikh R, Lairson D. Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007-2010 after the 2006 introduction of bevacizumab. Lung Cancer. 2015;90:442-50 pubmed publisher
    ..A clinical guideline may help the appropriate use of costly treatment modalities and minimize racial/geographic disparities. ..
  9. Chen Y, Lairson D, Chan W, Du X. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma. Ann Hematol. 2018;97:851-863 pubmed publisher
    ..PI plus IMiD combination therapies were associated with significantly higher risk for anemia, neutropenia, and thromboembolic events. ..

More Information


  1. Ludwig M, Kuban D, Strom S, Du X, Lopez D, Yamal J. The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation. BMC Cancer. 2015;15:190 pubmed publisher
    ..Increasing the duration of ADT beyond 6 months did not reduce the risk of biochemical failures. Better understanding the benefit of ADT in the era of dose escalation will require a randomized clinical trial. ..
  2. Du X, Zhang Y, Hardy D. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer. Cancer Causes Control. 2016;27:695-707 pubmed publisher
    ..Use of ESAs was significantly associated with substantially increased risks of MDS. These findings support those of previous studies. ..
  3. Liu Z, Zhang K, Du X. Risks of developing breast and colorectal cancer in association with incomes and geographic locations in Texas: a retrospective cohort study. BMC Cancer. 2016;16:294 pubmed publisher
    ..There were geographic variations with cancer incidence clustered in high risk areas in Texas. Future studies may need to explore more factors that might explain income and cancer risk associations and their geographic variations. ..
  4. Poonawalla I, Piller L, Lairson D, Chan W, Du X. Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer. Womens Health Issues. 2016;26:574-83 pubmed publisher
    ..An increased risk of TEEs was observed in elderly patients with ovarian cancer who received ESA + CSF. The risk-benefit ratio for administering HGF should be carefully evaluated, especially among those 85 years and older. ..
  5. Yang J, Du X, Li S, Wu Y, Lv M, Dong D, et al. The risk and survival outcome of subsequent primary colorectal cancer after the first primary colorectal cancer: cases from 1973 to 2012. BMC Cancer. 2017;17:783 pubmed publisher
    ..The different survival outcomes in CRC survivors suffering from SPCRC were largely explained by the patient age but not by the prior tumor location. ..
  6. Chen Y, Lairson D, Chan W, Du X. Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort. Med Oncol. 2017;34:153 pubmed publisher
    ..The survival benefit was significant across different demographic and patient characteristics. However, there were still a substantial number of MM patients not receiving anti-MM therapy. ..